SCHEMBL3669428

SCHEMBL3669428

CCCNC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 0.87
HIPK2 Q9H2X6 14/20 0.79
DAPK3 O43293 13/20 0.79
CLK2 P49760 13/20 0.79
CDK5 Q00535 13/20 0.79
DYRK1A Q13627 13/20 0.79
MAP4K5 Q9Y4K4 12/20 0.79
PAK4 O96013 12/20 0.79
PRKX P51817 12/20 0.79
CDK2 P24941 12/20 0.79
MELK Q14680 11/20 0.79
CSNK1A1 P48729 11/20 0.79
CDK7 P50613 11/20 0.79
CDK9 P50750 10/20 0.79
PRKACA P17612 8/20 0.79
ROCK2 O75116 8/20 0.79
MAP4K2 Q12851 8/20 0.79
PIM1 P11309 7/20 0.79
CLK4 Q9HAZ1 7/20 0.79
PRKD3 O94806 6/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668495 0.93 CDC7 (1.00) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL3666733 0.88 CDC7 (1.00) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL3666765 0.87 CDC7 (0.81) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL3667778 0.84 CDC7 (1.00) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL3667440 0.84 CDC7 (0.82) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL3666862 0.84 CDC7 (1.00) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL4289209 0.83 CDC7 (1.00) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL4300135 0.83 CDC7 (1.00) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL27788229 0.82 CDC7 (0.84) CDC7HIPK2DAPK3CLK2CDK5
SCHEMBL3668307 0.82 CDC7 (0.78) CDC7HIPK2DAPK3CLK2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885HIPK2 256/4885DAPK3 226/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885HIPK2 256/4885DAPK3 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.